Wire · opportunities
Celltrion's Actemra biosimilar 'Avtozma' wins U.S. approval for added pediatric COVID-19 indication |
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 11 October 2026 · Fusion42 review
Celltrion’s Avtozma, a biosimilar to Actemra, has received FDA approval for treating pediatric COVID-19 patients aged 2 years and older, expanding its U.S. treatment indications and addressing a critical gap in pediatric severe COVID-19 care.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You now have FDA-backed access to hospital-administered biosimilar treatments for pediatric COVID-19 patients, opening a critical segment with fewer options. Sharpen your approach to engage pediatric and emergency specialists who hold prescribing influence in this newly expanded market.
◆ Coverage
1 source · 11 Oct 2026
◆ Related on Wire
◆ Topics